COPENHAGEN, Denmark — October 7, 2025 — Leads & Copy — Pulse Biosciences, Inc. (Nasdaq: PLSE) will present early clinical data on the treatment of atrial fibrillation (AF) using the nPulse™ Cardiac Surgical System at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting from October 8-11 in Copenhagen, Denmark.
The presentation will highlight the use of nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy. Paul LaViolette, Co-Chairman and CEO of Pulse Biosciences, noted the FDA’s recent IDE study approval as a milestone in developing the technology for AF treatment. He also expressed enthusiasm for the early clinical evidence supporting the safety and efficacy of nPulse™.
Events featuring the nPulse™ Cardiac Surgical System include:
-
Wednesday, October 8, 2025: Acquired Cardiac Techno-College – Part 1, Presentation | Pulsed Field Ablation (Live in a box 3D), 9:30am – 12:30 pm (Presentation @ 10:40), Bella Center Copenhagen, Hall A1, featuring Bart van Putte, MD, St. Antonius Hospital, Nieuwegein, The Netherlands.
-
Friday, October 10, 2025: Thoracic Moderated e-Poster Presentation | First-In-Human Study Using Nanosecond Pulsed Field Ablation (nsPFA) for Surgical Left Atrial Box Isolation with Electroanatomical Mapping Follow-up, 12:30pm – 1:00 pm, Bella Center Copenhagen, Moderated e-Poster Station 2, featuring Bart van Putte, MD, St. Antonius Hospital, Nieuwegein, The Netherlands.
Pulse Biosciences is a bioelectric medicine company focused on health innovation to improve patient quality of life. Their nPulse™ technology delivers nanosecond pulses of electrical energy to clear cells non-thermally while sparing adjacent noncellular tissue. The company is developing nPulse for atrial fibrillation treatment and surgical soft tissue ablation.
Pulse Biosciences, nPulse, Vybrance, CellFX, Nano-Pulse Stimulation, NPS, nsPFA, CellFX nsPFA, nanosecond PFA and the stylized logos are trademarks of Pulse Biosciences, Inc.
Forward-Looking Statements
This release contains forward-looking statements regarding clinical successes, the safety and effectiveness of the nPulse Cardiac Surgical System, and the company’s future clinical and regulatory initiatives. These statements are based on current expectations and are subject to risks and uncertainties. Actual results may differ due to various factors detailed in Pulse Biosciences’ filings with the Securities and Exchange Commission. The company does not undertake to update this information, even if new details emerge.
Source: Pulse Biosciences
